GSK, Innoviva’s Trelegy Ellipta cleared for COPD

16th November 2017 Uncategorised 0

GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).

More: GSK, Innoviva’s Trelegy Ellipta cleared for COPD
Source: News